semaglutide risk of cancer GLP-1 drugs and cancer: the headline is exciting. The full picture is more nuanced. New research from @ascocancer 2026 shows patients on GLP-1 medications like were up to 50% less likely Semaglutide decelerates the growth and

HbA1c Decreased levels in HbA1c [92] were more strongly associated with fibrosis improvement in 39 Japanese patients with diabetes and NAFLD who underwent sequential liver biopsies

However, that slowdown also means food sits around in your gut longer, giving bacteria even more time to break it down and release hydrogen sulfide gas

Food and Drug Administration (FDA) , European Medicines Agency (EMA) , or any other national or international regulatory authority for clinical, medical, or veterinary use

Cagrilintide represents the breakthrough next-generation amylin agonist with weekly dosing, 10-12% monotherapy weight loss, and proven synergy with GLP-1 agonists when combined